{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:43:10Z","timestamp":1793392990191,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ERA-PerMed-JTC2018","award":["FIS PI16\/02057"],"award-info":[{"award-number":["FIS PI16\/02057"]}]},{"name":"ERA-PerMed-JTC2018","award":["PI19\/00588"],"award-info":[{"award-number":["PI19\/00588"]}]},{"name":"ERA-PerMed-JTC2018","award":["PI19\/00815"],"award-info":[{"award-number":["PI19\/00815"]}]},{"name":"ERA-PerMed-JTC2018","award":["DTS18\/00032"],"award-info":[{"award-number":["DTS18\/00032"]}]},{"name":"KIDNEY ATTACK","award":["AC18\/00064"],"award-info":[{"award-number":["AC18\/00064"]}]},{"name":"PERSTIGAN","award":["AC18\/00071"],"award-info":[{"award-number":["AC18\/00071"]}]},{"name":"PERSTIGAN","award":["ISCIII-RETIC REDinREN RD016\/0009"],"award-info":[{"award-number":["ISCIII-RETIC REDinREN RD016\/0009"]}]},{"name":"Fondos FEDER"},{"name":"FRIAT"},{"name":"Sociedad Espa\u00f1ola de Nefrolog\u00eda, Comunidad de Madrid","award":["B2017\/BMD-3686"],"award-info":[{"award-number":["B2017\/BMD-3686"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic kidney disease (CKD) patients are at an increased risk of cardiovascular disease (CVD) and statins may not be protective in advanced CKD. The reasons for the limited efficacy of statins in advanced CKD are unclear, but statins may increase plasma levels of the highly atherogenic molecule lipoprotein(a), also termed Lp(a), as well as PCSK9 (protein convertase subtilisin\/kexin type 9) levels. Lp(a) has also been linked to calcific aortic stenosis, which is common in CKD. Moreover, circulating Lp(a) levels increase in nephrotic syndrome with declining renal function and are highest in patients on peritoneal dialysis. Thus, the recent publication of the Phase 2 randomized controlled trial of pelacarsen [also termed AKCEA-APO(a)-LRx and TQJ230], a hepatocyte-directed antisense oligonucleotide targeting the LPA gene messenger RNA, in persons with CVD should be good news for nephrologists. Pelacarsen safely and dose-dependently decreased Lp(a) levels by 35\u201380% and a Phase 3 trial [Lp(a)HORIZON, NCT04023552] is planned to run from 2020 to 2024. Unfortunately, patients with estimated glomerular filtration rate &amp;lt;60\u2009mL\/min or urinary albumin:creatinine ratio &amp;gt;100\u2009mg\/g were excluded from Phase 2 trials and those with \u2018significant kidney disease\u2019 will be excluded from the Phase 3 trial. Optimized exclusion criteria for Lp(a)HORIZON would provide insights into the role of Lp(a) in CVD in CKD patients.<\/jats:p>","DOI":"10.1093\/ckj\/sfaa001","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T20:10:07Z","timestamp":1580847007000},"page":"753-757","source":"Crossref","is-referenced-by-count":34,"title":["Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease"],"prefix":"10.1093","volume":"13","author":[{"given":"Raul","family":"Fernandez-Prado","sequence":"first","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz-Universidad Autonoma de Madrid and Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vanessa","family":"Perez-Gomez","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz-Universidad Autonoma de Madrid and Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz-Universidad Autonoma de Madrid and Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2020102117150382000_sfaa001-B1","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"key":"2020102117150382000_sfaa001-B2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nefro.2018.09.002","article-title":"The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem","volume":"39","author":"Ortiz","year":"2019","journal-title":"Nefrologia"},{"key":"2020102117150382000_sfaa001-B3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ckj\/sfz007","article-title":"Clarifying the concept of chronic kidney disease for non-nephrologists","volume":"12","author":"Perez-Gomez","year":"2019","journal-title":"Clin Kidney J"},{"key":"2020102117150382000_sfaa001-B4","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"2020102117150382000_sfaa001-B5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/toxins10060237","article-title":"Deleting death and dialysis: conservative care of cardio-vascular risk and kidney function loss in chronic kidney disease (CKD)","volume":"10","author":"Vanholder","year":"2018","journal-title":"Toxins (Basel)"},{"key":"2020102117150382000_sfaa001-B6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ckj\/sfz126","article-title":"The chaos of hypertension guidelines for chronic kidney disease patients","volume":"12","author":"Castillo-Rodriguez","year":"2019","journal-title":"Clin Kidney J"},{"key":"2020102117150382000_sfaa001-B7","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH","volume":"32","author":"Sarafidis","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2020102117150382000_sfaa001-B8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1161\/HYPERTENSIONAHA.115.06895","article-title":"Hypertension in chronic kidney disease Part 1: out-of-office blood pressure monitoring: methods, thresholds, and patterns","volume":"67","author":"Parati","year":"2016","journal-title":"Hypertension"},{"key":"2020102117150382000_sfaa001-B9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/HYPERTENSIONAHA.115.06896","article-title":"Hypertension in chronic kidney disease Part 2: role of ambulatory and home blood pressure monitoring for assessing alterations in blood pressure variability and blood pressure profiles","volume":"67","author":"Parati","year":"2016","journal-title":"Hypertension"},{"key":"2020102117150382000_sfaa001-B10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M13-2453","article-title":"Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline","volume":"160","author":"Tonelli","year":"2014","journal-title":"Ann Intern Med"},{"key":"2020102117150382000_sfaa001-B11","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2020102117150382000_sfaa001-B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-017-0858-2","article-title":"Lipid management in chronic kidney disease: systematic review of PCSK9 targeting","volume":"78","author":"Zheng-Lin","year":"2018","journal-title":"Drugs"},{"key":"2020102117150382000_sfaa001-B13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.07.008","article-title":"Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: pooled analysis of nine ODYSSEY trials of alirocumab versus control","volume":"288","author":"Vallejo-Vaz","year":"2019","journal-title":"Atherosclerosis"},{"key":"2020102117150382000_sfaa001-B14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2020102117150382000_sfaa001-B15"},{"key":"2020102117150382000_sfaa001-B16"},{"key":"2020102117150382000_sfaa001-B17"},{"key":"2020102117150382000_sfaa001-B18"},{"key":"2020102117150382000_sfaa001-B19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"2020102117150382000_sfaa001-B20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14728222.2019.1620206","article-title":"An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients","volume":"23","author":"Bermudez-Lopez","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"2020102117150382000_sfaa001-B21","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020102117150382000_sfaa001-B22","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2020102117150382000_sfaa001-B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2020102117150382000_sfaa001-B24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","article-title":"Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome","volume":"119","author":"Wanner","year":"1993","journal-title":"Ann Intern Med"},{"key":"2020102117150382000_sfaa001-B25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2169\/internalmedicine.55.5473","article-title":"Serum autotaxin levels are associated with proteinuria and kidney lesions in Japanese Type 2 diabetic patients with biopsy-proven diabetic nephropathy","volume":"55","author":"Shimizu","year":"2016","journal-title":"Intern Med"},{"key":"2020102117150382000_sfaa001-B26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/j.ackd.2019.10.004","article-title":"Valvular calcification in chronic kidney disease","volume":"26","author":"Brandenburg","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"2020102117150382000_sfaa001-B27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehz776","article-title":"Statins and increases in Lp(a): an inconvenient truth that needs attention","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"2020102117150382000_sfaa001-B28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/eci.12661","article-title":"PCSK9 in diabetic kidney disease","volume":"46","author":"Elewa","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"2020102117150382000_sfaa001-B29","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER Trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2020102117150382000_sfaa001-B30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2020102117150382000_sfaa001-B31"},{"key":"2020102117150382000_sfaa001-B32"},{"key":"2020102117150382000_sfaa001-B33","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"2020102117150382000_sfaa001-B34","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2020102117150382000_sfaa001-B35","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1161\/ATVBAHA.119.311574","article-title":"Plaque calcification: do lipoproteins have a role?","volume":"39","author":"Akers","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020102117150382000_sfaa001-B36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.05440517","article-title":"The effect of extended release niacin on markers of mineral metabolism in CKD","volume":"13","author":"Malhotra","year":"2018","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/5\/753\/33980516\/sfaa001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/5\/753\/33980516\/sfaa001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:09:19Z","timestamp":1695712159000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/13\/5\/753\/5733752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,11]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa001","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,2,11]]}}}